Up a level |
Chekerov, Radoslav, Hilpert, Felix, Mahner, Sven, El-Balat, Ahmed, Harter, Philipp, De Gregorio, Nikolaus, Fridrich, Claudius, Markmann, Susanne, Potenberg, Jochem, Lorenz, Ralf, Oskay-Oezcelik, Guelten, Schmidt, Marcus ORCID: 0000-0003-1365-2414, Krabisch, Petra, Lueck, Hans-Joachim, Richter, Rolf, Braicu, Elena Ioana, du Bois, Andreas and Sehouli, Jalid (2018). Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol., 19 (9). S. 1247 - 1259. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488
von Minckwitz, Gunter, Schweller, Kathrin, Schmidt, Marcus ORCID: 0000-0003-1365-2414, Barinoff, Jana, Mundhenke, Christoph ORCID: 0000-0002-6989-6250, Cufer, Tanja, Maartense, Eduard ORCID: 0000-0002-5891-031X, de Jongh, Felix E., Baumann, Klaus H., Bischoff, Joachim, Harbeck, Nadia, Lueck, Hans-Joachim, Maass, Nicolai, Zielinski, Christoph, Andersson, Michael, Stein, Robert C., Nekljudova, Valentina and Loibl, Sibylle (2011). Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur. J. Cancer, 47 (15). S. 2273 - 2282. OXFORD: ELSEVIER SCI LTD. ISSN 0959-8049